D. E. Shaw & Co., Inc. Lyell Immunopharma, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 472,626 shares of LYEL stock, worth $288,301. This represents 0.0% of its overall portfolio holdings.
Number of Shares
472,626Holding current value
$288,301% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding LYEL
# of Institutions
121Shares Held
142MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$12.3 Million30.81% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$9.21 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$9.21 Million13.96% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$8.23 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$6.14 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $151M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...